EUCTR2017-001103-77-GB进行中(未招募)1 期
A phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed InaCTivated inflUenza vaccine in adultS aged 65 years and above - INVICTUS
Vaccitech Limited0 个研究点目标入组 862 人开始时间: 2018年5月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 发起方
- 入组人数
- 862
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •-Volunteer is willing and has capacity to provide written informed consent for participation in the trial (in the Investigator’s opinion).
- •-Male or female adults, aged 65 years and above
- •-Able and willing (in the Investigator’s opinion) to comply with all study requirements
- •-Willing to allow the investigators to discuss the volunteer’s medical history with their General Practitioner
- •-Eligible to receive seasonal influenza vaccine
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2030
排除标准
- •-Any history of anaphylaxis in reaction to vaccination, history of allergic disease or reactions likely to be exacerbated by any component of the vaccine (e.g. egg allergy).
- •-Ongoing terminal illness with a life expectancy estimated to be approximately <6 months.
- •-Continuous use of oral anticoagulants, such as coumarins and related anticoagulants (i.e. warfarin) or novel oral anticoagulants (i.e. apixaban, rivaroxaban, dabigatran and edoxaban)
- •-Any other significant disease, disorder or finding (including blood test results), which, in the opinion of the Investigators, would either put the volunteer at risk because of participation in the study, or may influence the result of the study
- •-Participation in another clinical trial of an investigational medicinal product in the 30 days preceding enrolment, or planned use during the study period
- •-Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data
- •- Receipt of annual seasonal influenza vaccine prior to enrolment (for the same influenza season volunteers are recruited in)
- •-Not willing to comply with study procedures
研究者
相似试验
进行中(未招募)
1 期
A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab plus Lenalidomide in Patients with Relapsed or Refractory Follicular LymphomaFollicular lymphomaMedDRA version: 19.0Level: LLTClassification code 10016904Term: Follicle centre lymphoma, follicular grade I, II, III NOSSystem Organ Class: 100000004864EUCTR2015-002467-42-FRF. Hoffmann-La Roche Ltd38
进行中(未招募)
1 期
A Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination with Atezolizumab plus Polatuzumab Vedotin in Patients with Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination with Atezolizumab plus Polatuzumab Vedotin in Patients with Relapsed or Refractory Diffuse large B-cell LymphomaFollicular Lymphoma (FL) or Diffuse Large B-cell Lymphoma (DLBCL)MedDRA version: 20.0Level: LLTClassification code 10016904Term: Follicle centre lymphoma, follicular grade I, II, III NOSSystem Organ Class: 100000004864EUCTR2015-004845-25-DEF. Hoffmann-La Roche Ltd.36
进行中(未招募)
1 期
A Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination with Atezolizumab plus Polatuzumab Vedotin in Patients with Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination with Atezolizumab plus Polatuzumab Vedotin in Patients with Relapsed or Refractory Diffuse large B-cell LymphomaEUCTR2015-004845-25-PLF. Hoffmann-La Roche Ltd36
进行中(未招募)
1 期
A Study of MPDL3280A plus Obinutuzumab and Bendamustine or Obinutuzumab and CHOP in Patients with Follicular Lymphoma or DiffuseLarge B-Cell LymphomaFollicular lymphoma or diffuse large B-cell lymphomaMedDRA version: 20.0Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10016904Term: Follicle centre lymphoma, follicular grade I, II, III NOSSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10012820Term: Diffuse large B-cell lymphoma NOSSystem Organ Class: 100000004864EUCTR2015-001364-19-ITF. HOFFMANN - LA ROCHE LTD.91
进行中(未招募)
1 期
Study of a combination therapy in patients with Waldenstrom Macroglobulinemia and active disease not previously treatedEUCTR2013-002388-25-ITAzienda Ospedaliera Ospedali Riuniti Marche Nord40
